Taurocholic acid - Satiogen Pharmaceuticals

Drug Profile

Taurocholic acid - Satiogen Pharmaceuticals

Alternative Names: sodium taurocholate - Satiogen Pharmaceuticals; taurocholate - Satiogen Pharmaceuticals

Latest Information Update: 16 Sep 2015

Price : $50

At a glance

  • Originator Satiogen Pharmaceuticals
  • Class Antihyperglycaemics; Bile acids and salts; Cholic acids; Obesity therapies; Small molecules
  • Mechanism of Action GPBAR1 protein agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Obesity; Type 2 diabetes mellitus

Highest Development Phases

  • Phase II Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 28 May 2014 Taurocholic acid is still in phase I/II trials for Type-2 diabetes mellitus and Obesity in United Arab Emirates
  • 02 May 2014 Taurocholic acid - Satiogen Pharmaceuticals is available for licensing for Type-II diabetes mellitus and Obesity (excluding USA) as of 02 May 2014. www.satiogen.com
  • 03 May 2011 Satiogen Pharmaceuticals completes enrolment in its phase I trial in healthy volunteers in Australia (ACTRN12611000071921)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top